Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.

Br J Cancer · 2009 · PMC2720232 · PMID 19603024

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

As this association was highly significant for patients receiving oxaliplatin, irinotecan or both, as well as for patients receiving bevacizumab or not, the conservative interpretation is that BRAF mutation is a prognostic rather than a predictive marker.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.